Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2019 Sep 23;19(1):221–230. doi: 10.1158/1535-7163.MCT-19-0103

Figure 6.

Figure 6.

Targeting Nrf2/GSH axis for IDH1-mutated cancers

Cancer-associated IDH1 mutants cause metabolic deficiency and accumulation of oxidative stress. Nrf2 plays a key protective role in IDH1-mutated cells, by transcribing GSH synthesis enzymes. The enhanced de novo GSH synthesis neutralizes excessive ROS, and therefore avoids oxidative damages to macromolecules. Targeting Nrf2/GSH could be a novel therapeutic strategy in this type of human malignancies.